Chronic beryllium disease: an updated model interaction between innate and acquired immunity.
During the last decade, there have been concerted efforts to reduce beryllium (Be) exposure in the workplace and thereby reduce potential cases of this occupational lung disorder. Despite these efforts, it is estimated that there are at least one million Be-exposed individuals in the U.S. who are potentially at risk for developing chronic beryllium disease (CBD). Previously, we reviewed the current CBD literature and proposed that CBD represents a model interaction between innate and acquired immunity (Sawyer et al., Int Immunopharmacol 2:249-261, 2002). We closed this review with a section on "future directions" that identified key gaps in our understanding of the pathogenesis of CBD. In the intervening period, progress has been made to fill in some of these gaps, and the current review will provide an update on that progress. Based on recent findings, we provide a new hypothesis to explain how Be drives sustained chronic inflammation and granuloma formation in CBD leading to progressive compromised lung function in CBD patients. This paradigm has direct implications for our understanding of the development of an immune response to Be, but is also likely applicable to other immune-mediated lung diseases of known and unknown etiology.
Sawyer
Richard T
RT
Asthma, Allergy and Inflammation Branch, Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Disease, National Institutes of Health, 6610 Rockledge Drive, Bethesda, MD, USA.
Maier
Lisa A
LA
D000818:Animals; D001607:Berylliosis / Q000276:immunology* / Q000473:pathology; D001608:Beryllium / Q000276:immunology; D002908:Chronic Disease; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D018448:Models, Immunological
D001608:Beryllium